JP2019520038A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019520038A5 JP2019520038A5 JP2018554562A JP2018554562A JP2019520038A5 JP 2019520038 A5 JP2019520038 A5 JP 2019520038A5 JP 2018554562 A JP2018554562 A JP 2018554562A JP 2018554562 A JP2018554562 A JP 2018554562A JP 2019520038 A5 JP2019520038 A5 JP 2019520038A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- cancer
- cell receptor
- peptide according
- fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 22
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 11
- 108091008874 T cell receptors Proteins 0.000 claims 9
- 239000012634 fragment Substances 0.000 claims 9
- 210000001744 T-lymphocyte Anatomy 0.000 claims 6
- 210000004027 cell Anatomy 0.000 claims 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 239000003446 ligand Substances 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 239000004480 active ingredient Substances 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000012528 membrane Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 108091023037 Aptamer Proteins 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 102000043129 MHC class I family Human genes 0.000 claims 1
- 108091054437 MHC class I family Proteins 0.000 claims 1
- 102000043131 MHC class II family Human genes 0.000 claims 1
- 108091054438 MHC class II family Proteins 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000033749 Small cell carcinoma of the bladder Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 210000004443 dendritic cell Anatomy 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000012636 effector Substances 0.000 claims 1
- 210000003238 esophagus Anatomy 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 238000004108 freeze drying Methods 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 201000010175 gallbladder cancer Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 230000003308 immunostimulating effect Effects 0.000 claims 1
- 108010028930 invariant chain Proteins 0.000 claims 1
- 239000012931 lyophilized formulation Substances 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 210000000822 natural killer cell Anatomy 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 239000003381 stabilizer Substances 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 201000007710 urinary bladder small cell neuroendocrine carcinoma Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
- 239000013598 vector Substances 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021114872A JP2021181442A (ja) | 2016-04-21 | 2021-07-12 | 黒色腫およびその他のがんに対する免疫療法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662325773P | 2016-04-21 | 2016-04-21 | |
| GB1606919.7 | 2016-04-21 | ||
| GB201606919 | 2016-04-21 | ||
| US62/325,773 | 2016-04-21 | ||
| PCT/EP2017/059016 WO2017182395A1 (en) | 2016-04-21 | 2017-04-13 | Immunotherapy against melanoma and other cancers |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021114872A Division JP2021181442A (ja) | 2016-04-21 | 2021-07-12 | 黒色腫およびその他のがんに対する免疫療法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019520038A JP2019520038A (ja) | 2019-07-18 |
| JP2019520038A5 true JP2019520038A5 (OSRAM) | 2020-05-07 |
Family
ID=58579156
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018554562A Pending JP2019520038A (ja) | 2016-04-21 | 2017-04-13 | 黒色腫およびその他のがんに対する免疫療法 |
| JP2021114872A Pending JP2021181442A (ja) | 2016-04-21 | 2021-07-12 | 黒色腫およびその他のがんに対する免疫療法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021114872A Pending JP2021181442A (ja) | 2016-04-21 | 2021-07-12 | 黒色腫およびその他のがんに対する免疫療法 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US10519216B2 (OSRAM) |
| JP (2) | JP2019520038A (OSRAM) |
| CL (3) | CL2018002969A1 (OSRAM) |
| CO (1) | CO2018012294A2 (OSRAM) |
| CR (3) | CR20200608A (OSRAM) |
| IL (1) | IL262503A (OSRAM) |
| MX (1) | MX2018012758A (OSRAM) |
| PH (1) | PH12018502159A1 (OSRAM) |
| SG (1) | SG10202006117QA (OSRAM) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111643524B (zh) | 2013-03-01 | 2023-09-05 | 美国卫生和人力服务部 | 从外周血中产生肿瘤反应性t细胞富集群的方法 |
| GB201408100D0 (en) * | 2014-05-07 | 2014-06-18 | Sec Dep For Health The | Detection method |
| GB201700621D0 (en) | 2017-01-13 | 2017-03-01 | Guest Ryan Dominic | Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue |
| JP7712207B2 (ja) | 2018-10-19 | 2025-07-23 | ザ フランシス クリック インスティチュート リミティッド | 新規な癌抗原及び方法 |
| JP2022539585A (ja) * | 2019-07-05 | 2022-09-12 | ザ フランシス クリック インスティチュート リミティッド | 新規な癌抗原及び方法 |
| JP2023507432A (ja) | 2019-12-20 | 2023-02-22 | インスティル バイオ （ユーケイ） リミテッド | 腫瘍浸潤リンパ球を単離するためのデバイスおよび方法ならびにそれらの使用 |
| CN119943275A (zh) * | 2024-12-13 | 2025-05-06 | 南方医科大学南方医院 | 神经酰胺作为标志物在预测肝细胞癌微血管侵犯风险中的应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001053312A1 (en) | 1999-12-23 | 2001-07-26 | Hyseq, Inc. | Novel nucleic acids and polypeptides |
| CA2343602A1 (en) | 2000-04-18 | 2001-10-18 | Genset | Est's and encoded human proteins |
| EP1578371A4 (en) | 2002-08-19 | 2009-05-20 | Genentech Inc | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING TUMORS |
| US8088976B2 (en) | 2005-02-24 | 2012-01-03 | Monsanto Technology Llc | Methods for genetic control of plant pest infestation and compositions thereof |
| ES2341802T3 (es) | 2005-09-05 | 2010-06-28 | Immatics Biotechnologies Gmbh | Peptidos asociados a tumores unidos promiscuamente a moleculas del antigeno de leucocito humano (hla) de clase ii. |
| US20080107668A1 (en) | 2006-08-30 | 2008-05-08 | Immunotope, Inc. | Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
| EP1961825A1 (en) * | 2007-02-26 | 2008-08-27 | INSERM (Institut National de la Santé et de la Recherche Medicale) | Method for predicting the occurrence of metastasis in breast cancer patients |
| GB201004551D0 (en) | 2010-03-19 | 2010-05-05 | Immatics Biotechnologies Gmbh | NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer |
| WO2012152811A1 (en) * | 2011-05-12 | 2012-11-15 | Noviogendix Research B.V. | Molecular markers in prostate cancer |
| HK1206601A1 (en) | 2012-04-02 | 2016-01-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of biologics and proteins associated with human disease |
| GB201411037D0 (en) | 2014-06-20 | 2014-08-06 | Immatics Biotechnologies Gmbh | Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemai (CLL) |
-
2017
- 2017-04-13 CR CR20200608A patent/CR20200608A/es unknown
- 2017-04-13 CR CR20180551A patent/CR20180551A/es unknown
- 2017-04-13 SG SG10202006117QA patent/SG10202006117QA/en unknown
- 2017-04-13 JP JP2018554562A patent/JP2019520038A/ja active Pending
- 2017-04-13 MX MX2018012758A patent/MX2018012758A/es unknown
- 2017-04-13 CR CR20200607A patent/CR20200607A/es unknown
-
2018
- 2018-10-08 PH PH12018502159A patent/PH12018502159A1/en unknown
- 2018-10-18 CL CL2018002969A patent/CL2018002969A1/es unknown
- 2018-10-21 IL IL262503A patent/IL262503A/en unknown
- 2018-11-14 CO CONC2018/0012294A patent/CO2018012294A2/es unknown
-
2019
- 2019-07-05 US US16/503,901 patent/US10519216B2/en active Active
- 2019-07-05 US US16/503,882 patent/US10435455B1/en active Active
-
2020
- 2020-12-18 CL CL2020003293A patent/CL2020003293A1/es unknown
- 2020-12-18 CL CL2020003292A patent/CL2020003292A1/es unknown
-
2021
- 2021-07-12 JP JP2021114872A patent/JP2021181442A/ja active Pending